TuHURA Biosciences, Inc. HURA 深 滬
等待開盤 03-26 09:30:00 美东时间
1.99
+0.020
+1.02%
華盛通- 最 高2.05
- 今 開2.02
- 成交量 36.01万股
- 最 低 1.915
- 昨 收 1.97
- 總市值 1.21亿
- 52周最高 4.44
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 0.41
- 委 比 -12.50%
- 總股本 6072.05万
- 歷史最高 190225.00
- 量 比 0.37
- 振 幅 6.85%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TuHURA Biosciences Regains Nasdaq Compliance
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26,
02-27 20:30
TuHURA Biosciences Files IND With FDA DHM1 For Study Of TBS-2025, VISTA Inhibiting Antibody, For Treatment Of mutNPM1 r/r AML In Combination With Menin Inhibitor
TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AMLTAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology
02-17 20:49
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
TuHURA Biosciences Granted Orphan Drug Designation From FDA For Its Treatment Of Stage IIB To Stage IV Cutaneous Melanoma
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and
02-02 20:48
TuHURA Biosciences Announces Kintara's REM-001 Trial Meets Primary Endpoint In Metastatic Cutaneous Breast Cancer
Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) HoldersTAMPA, Fla., Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology
2025-12-15 20:51
TuHURA Biosciences Provides Corporate Update Following Recent Financing
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted unde...
2025-12-11 20:30
TuHURA Biosciences Highlights Its Research On Potential Role Of DOR In Controlling Immunosuppressive Capabilities Of MDSCs In Oral Presentation At ASH Annual Meeting And Exposition
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by
2025-12-08 20:52
TuHURA Biosciences Q3 EPS $(0.14) Beats $(0.15) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 8.5 percent.
2025-11-14 20:39
TuHURA Biosciences To Present First Evidence Of Delta Opioid Receptor's Role In Reprogramming Immunosuppressive Cells At ASH 2025
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression
2025-11-03 22:15
TuHURA Biosciences Extends Warrant Expiration to 2030
An update from TuHURA Biosciences ( ($HURA) ) is now available. On June 2, 2025...
2025-09-12 05:03
